Michael P. LaQuaglia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael P. LaQuaglia has a total of 443 co-authors. Here are the top co-authors by number of shared publications:
- Emily K. Slotkin
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
30 shared publications - Paul A. Meyers
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
19 shared publications - Todd Erin Heaton
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
18 shared publications - Elisa de Stanchina
Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA
17 shared publications - Michael V. Ortiz
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
17 shared publications Neerav Shukla
17 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Optimization efforts to procure patient tumors, establish PDX tumor models and cryopreserve PDX tumor specimen.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Optimization efforts to procure patient tumors, establish PDX tumor models and cryopreserve PDX tumor specimen.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Comparative analysis of mutations in patient source tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Comparative analysis of mutations in patient source tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Validation of a EPB41L2::RAF1 gene fusion in an osteosarcoma PDX model.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Validation of a EPB41L2::RAF1 gene fusion in an osteosarcoma PDX model.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Evaluation of the EPB41L2::RAF1 gene fusion as an oncogenic driver and therapeutic target in osteosarcoma PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Evaluation of the EPB41L2::RAF1 gene fusion as an oncogenic driver and therapeutic target in osteosarcoma PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of sarcoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of sarcoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of osteosarcoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of osteosarcoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of neuroblastoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of neuroblastoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of Other Tumor cohort and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of Other Tumor cohort and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Molecular characterization of sarcoma PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Molecular characterization of sarcoma PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Molecular characterization of neuroblastoma PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Molecular characterization of neuroblastoma PDX models.